Browse
Submit Data
Databases
API
Help

Dataset Information

21 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II study of XELIRI and High-dose bevacizumab as second-line therapy in patients with metastatic colorectal cancer

ABSTRACT: Interventions: XELIRI plus bevacizumab therapy Bevacizumab 10mg/kg day1 Irinotecan 150mg/m2 day1 Capecitabin 2,000mg/m2/day day1-8 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2623833 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Multicenter randomized phase ll study of XELOX plus bevacizumab or XELIRI plusbevacizumab as first-line chemotherapy for metastatic or recurrent colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2,000mg/m2/day day1-15 XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 200mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15 Primary outcome(s): ORR; Overall response rate Study Design: Parallel Randomized

| 2622964 | ecrin-mdr-crc

A Phase II Study of Bi-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy

Project description:Interventions: XELIRI plus bevacizumab therapy Capecitabine: 2000 mg/m2 day1 to 8 CPT11 150mg/m2 day1 Bevacizumab: 10mg/kg day 1 The treatment is repeated every two weeks until disease progression or severe toxicity. Primary outcome(s): progression free survival and safety Study Design: Single arm Non-randomized

| 2624679 | ecrin-mdr-crc

Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Project description:Interventions: XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 160mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2624073 | ecrin-mdr-crc

Phase 2 study of bevacizumab and irinotecan as second-line therapy in patients with advanced colorectal cancer previously treated with oxaliplatin and bavacizumab

Project description:Interventions: Bevacizumab+Irinotecan Bevacizumab: 10mg/kg d.i.v. day1 Irinotecan:150mg/m2 d.i.v.day1 to be repeated every 2 weeks Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

| 2622484 | ecrin-mdr-crc

Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 irinotecan 130mg/m2 day1 Capecitabin 1600mg/m2/day day1-15 Primary outcome(s): ORR;Overall response rate Study Design: Single arm Non-randomized

| 2627045 | ecrin-mdr-crc

Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizmab for metastatic colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2000mg/m2/day day1-15 Primary outcome(s): ORR;Over response rate Study Design: Single arm Non-randomized

| 2626922 | ecrin-mdr-crc

A Phase I /II Study of Bi-weekly XELIRI with Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy.

Project description:Interventions: XELIRI+ bevacizumab Capecitabine:2000mg/m2/day d1-8 Irinotecan:180mg/m2 d1 Bevacizumab:5mg/kg d1 Q2w Primary outcome(s): Phase I part To determine Safety in 1st cycle by Bi-weekly XELIRI+bevacizumab. Phase II part Progression Free Survival Study Design: Single arm Non-randomized

| 2619445 | ecrin-mdr-crc

Randomized phase II study of adding steroid for prevention of venous pain in colorectal cancer patients who are receiving oxaliplatin through peripheral vein (APOLLO)

Project description:Interventions: XELOX Oxaliplatin 130mg/m2 day1 Capecitabine 2,000mg/m2 day1-14 every 3 weeks SOX Oxaliplatin 130mg/m2 day1 S-1 80-120mg/m2 day1-14 every 3 weeks Oxaliplatin is combined with dexamethasone (2 mg). XELOX Oxaliplatin 130mg/m2 day1 Capecitabine 2,000mg/m2 day1-14 every 3 weeks SOX Oxaliplatin 130mg/m2 day1 S-1 80-120mg/m2 day1-14 every 3 weeks Primary outcome(s): The incidence of venous pain:Grade>=2 Study Design: Parallel Randomized

| 2619736 | ecrin-mdr-crc

Phase II study of bevacizumab and irinotecan as second-line therapy in patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab

Project description:Interventions: 1) Bevacizumab 10mg/kg is administered by 10-30min. intravenous infusion, followed by irinotecan 150mg/m2 by 90 min infusion (2)Patients should be received this chemotherapy biweekly until disease progression Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2620667 | ecrin-mdr-crc

A Phase II Study of Bi-weekly XELOX with Bevacizumab for patient with Metastatic Colorectal Cancer as first-line chemotherapy

Project description:Interventions: XELIRI plus bevacizumab therapy /Capecitabine;2,000 mg/m2 day1-8(orally, day1 after dinner; day8 after breakfast) /Oxaliplatin 85 mg/m2 day1 /Bevacizumab: 5mg/kg day 1 The treatment is repeated every two weeks until disease progression or severe toxicity Primary outcome(s): progression free survival Study Design: Single arm Non-randomized

| 2625648 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data